CDK4 / 6 micromolecular fluorescent probe as well as preparation method and application thereof

By designing and preparing CDK4/6 small molecule fluorescent probes, the problem of lack of small molecule probes in the prior art for studying CDK4/6 protein interactions is solved, and high affinity and high sensitivity to CDK4/6 proteins are achieved. Detection has promoted in-depth understanding of the mechanism of action of CDK4/6 protein and the discovery of inhibitors.

CN118908958AActive Publication Date: 2024-11-08SHANDONG FIRST MEDICAL UNIV & SHANDONG ACADEMY OF MEDICAL SCI

Patent Information

Application Number
CN202410974834.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-19
Publication Date
2024-11-08
Estimated Expiration
2044-07-19

AI Technical Summary

Technical Problem

The lack of small molecule fluorescent probes for studying CDK4/6 protein interactions in the prior art limits the in-depth understanding of the mechanism of action of CDK4/6 protein and the discovery of effective inhibitors.

Method used

A CDK4/6 small molecule fluorescent probe was designed and prepared. By amidation and amide condensation reaction with Palbociclib compounds, a probe with specific binding capacity was generated for identification and labeling of CDK4/6 protein.

Benefits of technology

It realizes high affinity and high sensitivity detection for CDK4/6 protein, provides tools for identifying and labeling CDK4/6 protein, and has broad application prospects in physiological, pathological and anti-tumor evaluation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118908958A_ABST
    Figure CN118908958A_ABST
Patent Text Reader

Abstract

The invention discloses a CDK4 / 6 micromolecular fluorescent probe as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The CDK4 / 6 micromolecular fluorescent probe provided by the invention has a structure as shown in a formula (I), and the probe has novel response groups and good selectivity; the preparation method has the advantages of mild reaction conditions, cheap and easily available raw materials and simple operation and post-treatment; the affinity with CDK4 / 6 protein is high, and the sensitivity is high. # imgabs0 #
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of biomedicine technology, and in particular to a CDK4 / 6 small molecule fluorescent probe and a preparation method and application thereof. Background Art

[0002] The information disclosed in the background of the invention is only intended to enhance the understanding of the overall background of the invention and should not be necessarily regarded as an acknowledgment or any form of suggestion that the information constitutes the prior art already known to a person skilled in the art.

[0003] The cell cycle consists of four phases: S phase (mainly DNA replication), M phase (mainly mitosis), and two gaps between S and M (G1 and G2). A quiescent state called G0 also exists in non-proliferating cells. The cell cycle is controlled and regulated by various specific proteins, such as: cyclin-dependent kinases (CDKs), cyclins, and retinoblastoma protein (pRb). Cyclin-dependent kinases (CDKs) are a family of serine / threonine protein kinases. Disregulation of CDKs can lead to cell cycle imbalance and unlimited cell proliferation, thereby promoting the occurrence and development of malignant tumors. CDKs bind to their corresponding cyclins and form functional heterodimer complexes. So far, 20 CDKs and 29 cyclins have been discovered. CDKs include cell cycle-related CDKs (CDK1, CDK2, CDK4, and CDK6) and transcription CDKs (CDK7-9, CDK11-13, CDK19). According to their functions, they can be divided into two subfamilies: CDKs 1–6, 11, and 14-18 for cell cycle regulation, and CDKs 7-13, 19, and 20 for transcription. The activation of CDKs is controlled by the association with their regulatory subunits (cyclins) and phosphorylated inhibitory proteins. CDK4, which is closely related to CDK6, plays a crucial role in the transition from G1 to S when it coordinates with cyclin D by phosphorylating pRb, which inhibits the transition from G1 to S phase in an unphosphorylated state. Aberrations of the cyclin D-CDK4 / 6-INK4-pRb pathway frequently occur in tumors, so tumors are also considered cell cycle diseases. In particular, with the continuous research on the mechanism of cell cycle regulation making significant progress, CDKs play a central role in cell cycle regulation. Therefore, small molecule CDK inhibitors are a hot area of ​​research in anticancer chemotherapy.

[0004] An important topic in the study of CDK inhibitors is the testing and identification of combination therapy regimens involving CDK4 / 6 inhibitors (for the treatment of different tumor types). CDK4 / 6 inhibitors trigger cell cycle arrest in tumor cells and, in some cases, can trigger senescence. Among them, Palbociclib, a specific inhibitor of CDK4 / 6, has become a star drug in recent years for the treatment of breast cancer, especially estrogen receptor-positive breast cancer. It is crucial to identify combination therapies that convert CDK4 / 6 inhibitors from cytostatic compounds to cytotoxic compounds and release tumor cell killing. Whole-genome high-throughput screening and analysis of mouse cancer models and PDX will help to address this issue. Another unexplored area of ​​cyclin D-CDK4 / 6 biology is that these proteins may be involved in other pathologies, such as metabolic disorders. Research in this area may expand the use of CDK4 / 6 inhibitors to the treatment of other diseases. These issues ensure that CDK4 / 6 biology will remain an active area of ​​basic, translational, and clinical research in the coming years.

[0005] Small molecule fluorescent probes are fast, sensitive, high-throughput and easy to automate, and have important applications in protein labeling and imaging technology. At present, small molecule fluorescent probes have been widely used in the biological and pharmacological detection of important biological molecules such as proteins and nucleic acids, and are of great significance to the development of disease mechanism exploration, clinical diagnosis and drug screening. However, there are still few types of small molecule probes that can specifically bind to target proteins, mainly due to the lack of design and synthesis methods. In particular, there is currently no small molecule fluorescent probe for studying CDK4 / 6 protein-protein interactions. Summary of the invention

[0006] Based on the deficiencies of the prior art, the present invention provides a CDK4 / 6 small molecule fluorescent probe and a preparation method and application thereof. The probe can specifically bind to CDK4 / 6 protein. The application of this small molecule probe can provide a deeper understanding of the mechanism of action between CDK4 / 6 proteins and the discovery of more effective inhibitors.

[0007] In order to achieve the above object, the technical solution of the present invention is:

[0008] In the first aspect, a CDK4 / 6 small molecule fluorescent probe has a structure shown in formula (I):

[0009]

[0010] Wherein, R1 is selected from any one of the following structures:

[0011] or n=1, 2, 3 or 5.

[0012] In a second aspect, a CDK4 / 6 small molecule fluorescent probe has a structure shown in formula (I):

[0013]

[0014] Wherein, R1 is selected from any one of the following structures:

[0015] or

[0016] m=1 or 2.

[0017] In a third aspect, the preparation method of the above-mentioned CDK4 / 6 small molecule fluorescent probe comprises the following steps:

[0018] Palbociclib is subjected to an amidation reaction with a compound represented by formula (II) to generate a compound represented by formula (III), and the compound represented by formula (III) is subjected to an amide condensation reaction with dansyl chloride after deprotection to obtain a compound represented by formula (I);

[0019] n=1, 2, 3 or 5, formula (II);

[0020] n=1, 2, 3 or 5, formula (III);

[0021] Alternatively, Palbociclib is subjected to an amidation reaction with 3-(2-((tert-butoxycarbonyl)amino)ethoxy)propionic acid to generate a compound, and the generated compound is subjected to an amide condensation reaction with dansyl chloride after deprotection to obtain a compound represented by formula (I);

[0022] Alternatively, 7-(diethylamino)-2-oxo-2H-chromone-3-carboxylic acid is reacted with sulfuryl chloride to generate a carboxylic acid derivative, which is then reacted with the compound represented by formula (III) through a nucleophilic substitution reaction to obtain the compound represented by formula (I);

[0023] Alternatively, 4-(3-phenoxypropyl)-1,3-dioxane-2-en-2-one is reacted with chlorosulfonic acid through a sulfonation reaction to obtain an intermediate, the intermediate is subjected to an amidation reaction, and then reacted with the compound represented by formula (III) through a nucleophilic substitution reaction to obtain the compound represented by formula (I);

[0024] Alternatively, 4-(1,2,2-triphenylvinyl)benzoic acid and the compound represented by formula (III) are reacted by amide condensation to generate the compound represented by formula (I);

[0025] Alternatively, 4-chloro-7-nitrobenzo[c][1,2,5]oxadiazole and the compound represented by formula (III) are reacted by amide condensation to generate the compound represented by formula (I);

[0026] Alternatively, the compound represented by formula (IV) is subjected to a halogenation reaction and then reacted with 2,3,3-trimethylindole. The reaction product is reacted with the compound represented by formula (V), and then reacted with the compound represented by formula (III) or Palbociclib to generate the compound represented by formula (I) through an amide condensation reaction; the compound represented by formula (V) is obtained by alkylation of 2,3,3-trimethylindole;

[0027] n=1 or 2, formula (IV);

[0028] Optionally, the compound represented by formula (II) reacts with Palbociclib in the presence of DIEA and HATU to generate the compound represented by formula (III), the compound represented by formula (III) reacts with trifluoroacetic acid to remove the protecting group, and then undergoes an amide condensation reaction with dansyl chloride in the presence of DIEA to generate the compound represented by formula (I).

[0029] Optionally, SOCl2 is added to 7-(diethylamino)-2-oxo-2H-chromone-3-carboxylic acid under nitrogen protection, and DMF is added to react to obtain a carboxylic acid derivative, and the carboxylic acid derivative is sequentially added with DIEA and HATU to react, and then the compound represented by formula (III) is added to carry out a nucleophilic substitution reaction to generate a compound represented by formula (I).

[0030] Optionally, chlorosulfonic acid is added to 4-(3-phenoxypropyl)-1,3-dioxane-2-en-2-one under ice bath conditions, followed by heating under reflux to obtain an intermediate, triethylamine is added to the intermediate under ice bath conditions for reaction, dimethylammonium hydrochloride is then added for reaction, N,N-diisopropylethylamine is added for reaction, and then the compound represented by formula (III) is added for nucleophilic substitution reaction to generate the compound represented by formula (I).

[0031] Optionally, N,N-diisopropylethylamine and HATU are added to 4-(1,2,2-triphenylvinyl)benzoic acid in sequence for reaction, and then a nucleophilic substitution reaction is carried out with the compound represented by formula (III) to generate the compound represented by formula (I).

[0032] Optionally, 4-chloro-7-nitrobenzo[c][1,2,5]oxadiazole is added to N,N-diisopropylethylamine for reaction, and then undergoes a nucleophilic substitution reaction with the compound represented by formula (III) to generate the compound represented by formula (I).

[0033] Optionally, the compound represented by formula (IV) reacts with NaI under N2 reaction to undergo halogenation reaction; then ethyl acetate is added for reaction, and then 2,3,3-trimethylindole is added for reaction to obtain compound 04; 2,3,3-trimethylindole is refluxed with methyl iodide to precipitate crystals of compound 05; malondialdehyde diphenylamine hydrochloride is added to the reaction product 04 and mixed, and then acetic acid and acetic anhydride are added under nitrogen protection for reflux reaction; then compound 05, pyridine and acetic acid are added for reflux reaction to obtain compound 06; DIEA and HATU are added to compound 06 in sequence, and then the compound represented by formula (III) is added for nucleophilic substitution reaction to generate the compound represented by formula (I).

[0034]

[0035] Alternatively, after obtaining compound 06, DIEA and HATU are added to compound 06 in sequence, and then Palbociclib is added to carry out a nucleophilic substitution reaction to generate a compound represented by formula (I).

[0036] In a fourth aspect, the application of the CDK4 / 6 small molecule fluorescent probe described in the first and second aspects includes: application in identifying CDK4 / 6 protein and / or preparing a product for identifying CDK4 / 6 protein.

[0037] In a fifth aspect, the application of the CDK4 / 6 small molecule fluorescent probe described in the first aspect includes: application in cell cycle arrest and / or preparation of cell cycle arrest products;

[0038] Alternatively, the invention can be used in cancer cell fluorescence imaging and / or in the preparation of cancer cell fluorescence imaging products.

[0039] The beneficial effects of the present invention are:

[0040] 1. The probe response group of the present invention is novel and has good selectivity; the preparation method has mild reaction conditions, cheap and easily available raw materials, and simple operation and post-processing.

[0041] 2. The probe molecule of the present invention has strong biological activity, high affinity with CDK4 / 6 protein, and high sensitivity; it can be used to mark CDK4 / 6 protein and its highly expressed tumor cells or tissues; it can be used as a probe to identify CDK4 / 6 protein and CDK4 / 6 protein has broad application prospects in physiology, pathology and related diseases.

[0042] 3. The probe of the present invention can directly react to the inhibitory activity of the compound on CDK4 / 6 protein, and can be used for high-throughput screening of CDK4 / 6 protein inhibitors and their application in anti-tumor evaluation. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] The drawings constituting part of the present invention are used to provide a further understanding of the present invention. The exemplary embodiments of the present invention and their description are used to explain the present invention and do not constitute an improper limitation of the present invention. Obviously, for those skilled in the art, other drawings can be obtained based on these drawings without creative work.

[0044] Figure 1 A diagram showing the results of optical activity measurement in Example 4;

[0045] Figure 2 A diagram showing the results of cell activity assay in Example 6;

[0046] Figure 3 A diagram showing the cell imaging results of the probe molecule in Example 8. DETAILED DESCRIPTION

[0047] It should be noted that the following detailed descriptions are exemplary and are intended to provide further explanation of the present invention. Unless otherwise specified, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art to which the present invention belongs.

[0048] In the following embodiments, the abbreviations represent the following meanings:

[0049] DMSO: dimethyl sulfoxide;

[0050] DIEA: N,N-diisopropylethylamine;

[0051] HATU: 2-(7-azabenzotriazole)-N,N,N,N-tetramethyluronium hexafluorophosphate;

[0052] DMF: N,N-dimethylformamide;

[0053] TEA: triethylamine;

[0054] CDCl3: deuterated chloroform;

[0055] SOCl2: thionyl chloride, thionyl chloride;

[0056] Tris: tris(hydroxymethyl)aminomethane;

[0057] BSA: bovine serum albumin;

[0058] DTT: dithiothreitol;

[0059] ATP: adenosine triphosphate;

[0060] 1 H NMR: hydrogen nuclear magnetic resonance;

[0061] 13C NMR: carbon nuclear magnetic resonance;

[0062] HRMS(ESI): High resolution mass spectrometry (electrospray ionization).

[0063] The technical solution of the present invention is further described below in conjunction with specific embodiments.

[0064] Example 1

[0065] Preparation method of CDK4 / 6 small molecule fluorescent probe,

[0066] The reaction route is shown below:

[0067]

[0068] n=1,2,3 or 5.

[0069] The reaction steps include:

[0070] S1, reacting compound (1) and Palbociclib as raw materials to generate intermediate (3);

[0071] S2, adding trifluoroacetic acid to convert intermediate (3) into intermediate (4);

[0072] S3. Dansyl chloride is added to react with the intermediate (4) to obtain compound (6), which is the small molecule fluorescent probe targeting CDK4 / 6 protein shown.

[0073] Wherein, when n=1, 2, 3 or 5, compound (1) is compound (1a), (1b), (1c) and (1d), respectively; compound (3) is compound (3a), (3b), (3c) and (3d), respectively; compound (4) is compound (4a), (4b), (4c) and (4d), respectively; and compound (6) is compound (6a), (6b), (6c) and (6d), respectively.

[0074] When n=1, compound (1a) is Boc-beta-alanine, and the steps include:

[0075] S1. Dissolve Boc-beta-alanine (compound (1a), 51 mg, 0.268 mmol) in dichloromethane (5 mL), add DIEA (55 μM, 0.334 mmol) and HATU (165 mg, 0.446 mmol) and react at room temperature for one hour; then add Palbociclib (compound (2), 100 mg, 0.223 mmol) and react, stir at room temperature for 12 hours; then extract with dichloromethane, wash with 1M NaOH solution, remove the solvent, and obtain a yellow solid; purify the obtained compound by silica gel column chromatography, remove the solvent, and obtain a yellow solid. Dissolve the yellow solid in a solution of petroleum ether and ethyl acetate (6:1), filter, and obtain a yellow solid compound (3a), with a yield of 94.3%. Compound (3a), mp: 160-176℃. 1 H-NMR (400MHz, DMSO-d6) δ10.13(s,1H),8.96(s,1H),8.08(d,J=3.0Hz,1H),7.88(d,J=9. 0Hz,1H),7.51(dd,J=9.1,3.1Hz,1H),6.73(s,1H),5.83(p,J=8.7Hz,1H),3.61(d,J=5.5H z,5H),3.22-3.10(m,6H),2.42(s,3H),2.31(s,3H),2.25(s,2H),2.00(q,J=7.0,6.6Hz,1 H), 1.89 (s, 1H), 1.82-1.72 (m, 1H), 1.58 (d, J = 5.3Hz, 2H), 1.37 (s, 9H), 0.95-0.79 (m, 1H).

[0076] S2. Compound (3a) (130 mg, 0.21 mmol), 5 mL of trifluoroacetic acid and 5 mL of dichloromethane were placed in a 25 mL eggplant-shaped bottle and stirred to dissolve. After 2 h, the reaction was complete and the solvent was removed by vortexing. The pH was adjusted to 7-8 with saturated sodium bicarbonate. Water and dichloromethane were added for extraction and the mixture was dried by vortexing to obtain compound (4a) as a yellow solid (120 mg). The mixture was directly used for the next step without secondary purification.

[0077] S3. Compound (4a) (100 mg, 0.193 mmol) was dissolved in dichloromethane, DIEA (21 mg, 0.164 mmol) and dansyl chloride (compound (5), 72 mg, 0.231 mmol) were added, and the mixture was reacted at room temperature for 24 h. The reaction solution was extracted with dichloromethane, washed with 1M citric acid, dried and the solvent was removed by column chromatography. After the solvent was removed by removal, a yellow solid was obtained, which was dissolved in a solution of n-hexane and dichloromethane (7:1), filtered, and finally compound (6a), i.e., a small molecule fluorescent probe TYZJ-2202 targeting CDK4 / 6 protein, was obtained as a yellow solid with a yield of 48%. Small molecule fluorescent probe TYZJ-2202, mp: 160-167℃. 1 H-NMR (400MHz, DMSO-d6) δ10.14(s,1H),8.96(s,1H),8.47(d,J=8.5Hz,1H),8.28(d,J=8.7Hz,1H),8.15(dd,J=7. 3,1.2Hz,1H),8.05(d,J=3.0Hz,1H),7.95-7.85(m,2H),7.71-7.56(m,2H),7.47(dd,J=9.1,3.0Hz,1H),5.83(p,J= 8.8Hz,1H),3.51(t,J=5.1Hz,2H),3.40(d,J=4.6Hz,2H),3.05(dd,J=7.9,4.7Hz,6H),2.81(s,6H),2.45(d,J=7.0H z,2H),2.43(s,4H),2.31(s,3H),2.28-2.19(m,2H),1.89(s,2H),1.83-1.72(m,2H),1.60(dd,J=12.7,6.8Hz,2H). 13 C-NMR(100MHz,DMSO-d6)δ202.90,168.91,161.22,158.97,158.88,158.71,155.23 ,151.84,145.25,145.16,143.55,142.54,136.36,129.95,129.78,129.54,128.83 ,128.36,125.81,124.09,119.56,115.62,115.46,115.37,107.11,53.42,49.11,48.70,45.52,44.83,41.06,32.99,31.77,31.43,28.04,25.61,22.53,14.43,14.10.

[0078] When n=2, compound (1b) is N-BOC-GAMMA-aminobutyric acid, and the steps include:

[0079] S1. According to the above synthesis step S1 with n = 1, compound (1b) was used as a raw material to generate a yellow solid (3b) with a yield of 85.1%, mp: 202-214°C. 1 H-NMR (400MHz, DMSO-d6) δ10.13(s,1H),8.95(d,J=10.2Hz,1H),8.08(d,J=3.1Hz,1H),7. 88(d,J=9.1Hz,1H),7.58–7.44(m,1H),6.81(s,1H),5.83(t,J=8.9Hz,1H),3.60(s,6H),3. 17(s,2H),3.11(s,6H),2.95(d,J=6.3Hz,2H),2.42(s,3H),2.31(s,2H),2.25(s,2H),1.99 (s,1H),1.89(s,2H),1.77(s,2H),1.67–1.53(m,7H),1.36(d,J=10.3Hz,1H),0.85(s,1H).

[0080] S2. Compound (3b) (120 mg, 0.190 mmol), 5 mL of trifluoroacetic acid and 5 mL of dichloromethane were placed in a 25 mL eggplant-shaped bottle and stirred to dissolve. The reaction was completed after 2 h. The solvent was removed by vortexing. The pH was adjusted to 7-8 with saturated sodium bicarbonate. Water and dichloromethane were added for extraction and the mixture was dried by vortexing to obtain compound (4b) as a yellow solid (120 mg). The compound (4b) was directly used for the next step without secondary purification. Compound (4b) is also referred to as intermediate 2203-04 in Examples 2 and 3.

[0081] S3. Compound (4b) (120 mg, 0.225 mmol) was dissolved in dichloromethane, and DIEA (58 mg, 0.45 mmol) and dansyl chloride (compound (5), 84 mg, 0.27 mmol) were added. The mixture was reacted at room temperature for 24 h. The reaction solution was extracted with dichloromethane, washed with 1M citric acid, dried and the solvent was removed by column chromatography. After the solvent was removed by removal, a yellow solid was obtained. The yellow solid was dissolved in a solution of n-hexane and dichloromethane (7:1), filtered, and finally compound 6b, i.e., a small molecule fluorescent probe TYZJ-2203 targeting CDK4 / 6 protein, was obtained as a yellow solid with a yield of 46.5%. mp: 151-162℃. 1H-NMR (400MHz, DMSO-d6) δ10.14(s,1H),8.96(s,1H),8.46(d,J=8.5Hz,1H),8.31(d,J=8.6Hz,1H),8.17-8.0 4(m,2H),7.98-7.86(m,1H),7.61(dt,J=8.7,7.3Hz,2H),7.49(dd,J=9.1,3.0Hz,1H),7.25(d,J=7.5Hz,1H),5 .84(p,J=8.9Hz,1H),3.51(t,J=5.1Hz,2H),3.05(d,J=5.4Hz,4H),2.82(s,8H),2.43(s,3H),2.31(s,3H),2.3 0-2.23(m,5H),2.18(t,J=7.3Hz,2H),1.90(d,J=8.6Hz,2H),1.82-1.74(m,2H),1.57(dt,J=21.7,7.7Hz,4H). 13 C-NMR(100MHz,DMSO-d6)δ202.91,170.37,161.22,158.99,158.73,155.23,151.84 ,145.25,143.61,142.54,129.87,129.53,129.51,128.88,128.29,125.83,124.08, 119.55,115.55,107.12,60.23,53.40,49.18,48.84,45.53,44.74,42.52,42.42,41.08,31.78,31.42,29.55,28.04,25.60,25.16,22.53,21.23,14.56,14.43,14.10.

[0082] When n=3, compound (1c) is Boc-5-aminopentanoic acid, and the steps include:

[0083] S1, according to the synthesis steps of S1 of this example, compound (1c) as a raw material, and Palbociclib (compound (2)) synthesized a yellow solid (3c), the yield was 74.7%, mp165-177 ℃. 1H-NMR (400MHz, DMSO-d6) δ10.12(s,1H),8.96(s,1H),8.08(d,J=3.0Hz,1H),7.88(d,J=9.0Hz,1H),7 .50(dd,J=9.1,3.1Hz,1H),6.76(s,1H),5.90–5.67(m,1H),3.61(s,4H),3.14(d,J=21.3Hz,6H),2.8 9(q,J=6.6Hz,2H),2.42(s,3H),2.34(t,J=7.5Hz,2H),2.31(s,3H),2.24(d,J=10.1Hz,2H),1.99(p, J=7.1Hz,1H),1.89(s,2H),1.84–1.68(m,1H),1.65–1.55(m,2H),1.49(q,J=7.4Hz,2H),1.37(s,9H).

[0084] S2. The product (3c) (115 mg, 0.178 mmol), 5 mL of trifluoroacetic acid and 5 mL of dichloromethane were placed in a 25 mL eggplant-shaped bottle and stirred to dissolve. The reaction was completed after 2 h. The solvent was removed by vortexing. The pH was adjusted to 7-8 with saturated sodium bicarbonate. Water and dichloromethane were added for extraction and the mixture was dried by vortexing to obtain compound (4c), 115 mg of a yellow solid. The compound was directly used for the next step without secondary purification.

[0085] S3. Compound (4c) (115 mg, 0.211 mmol) was dissolved in dichloromethane, and DIEA (137 mg, 1.055 mmol) and dansyl chloride (compound (5), 78 mg, 0.252 mmol) were added successively. The mixture was reacted at room temperature for 24 h. The reaction solution was extracted with dichloromethane, washed with 1M citric acid, dried and the solvent was removed by column chromatography. After the solvent was removed by removal, a yellow solid was obtained. The yellow solid was dissolved in a solution of n-hexane and dichloromethane (7:1), filtered, and finally compound (6c), i.e., a small molecule fluorescent probe TYZJ-2201 targeting CDK4 / 6 protein, was obtained as a yellow solid with a yield of 48%. mp: 135-142℃. 1H-NMR (400MHz, DMSO-d6) δ10.15(s,1H),8.96(s,1H),8.46(d,J=8.5Hz,1H),8.31(d,J=8.6Hz,1H),8.15-8.06(m ,2H),7.93-7.85(m,2H),7.60(ddd,J=14.2,8.6,7.4Hz,2H),7.50(dd,J=9.1,3.0Hz,1H),7.25(d,J=7.5Hz,1H), 5.96-5.76(m,1H),3.57(s,2H),3.51(s,2H),3.18-3.06(m,7H),2.82(s,1H),2.43(s,3H),2.32(s,3H),2.20(t, J=7.0Hz,4H),1.89(s,3H),1.83-1.73(m,4H),1.66-1.55(m,2H),1.39(dq,J=12.0,5.7,4.7Hz,4H),1.23(s,1H). 13 C-NMR(100MHz,DMSO-d6)δ202.91,170.83,161.22,158.99,158.72,155.23,151.80,1 45.25,143.65,142.54,136.65,136.36,129.79,129.58,129.53,128.67,128.25,125. 86,124.04,119.63,115.55,115.52,107.11,53.41,49.37,48.95,45.53,45.02,42.68,42.58,41.12,32.01,31.78,31.42,29.27,28.03,25.60,22.53,22.24,14.43,14.10.

[0086] When n=5, compound (1d) is 7-(N-tert-butyloxycarbonylamino)heptanoic acid, and the steps include:

[0087] S1, according to the reaction steps of compound (3a) in this example, compound (1d) and Palbociclib (compound (2)) were used to synthesize a yellow solid (3d) with a yield of 68.3%, mp170-177°C. 1H-NMR (400MHz, DMSO-d6) δ10.13(s,1H),8.95(d,J=9.2Hz,1H),8.08(d,J=3.1Hz,1H),7.88(d,J=9.1Hz, 1H),7.59–7.36(m,1H),6.81(s,1H),6.01–5.71(m,1H),3.60(s,4H),3.17(s,2H),3.11(s,4H),2.95(d, J=6.3Hz,3H),2.45-2.39(m,3H),2.36(d,J=7.3Hz,2H),2.34-2.26(m,3H),2.25(s,2H),2.03-1.94(m,2 H),1.96-1.84(m,2H),1.83-1.72(m,2H),1.68-1.55(m,4H),1.36(d,J=10.3Hz,9H),0.94-0.73(m,1H).

[0088] S2. Compound (3d) (101 mg, 0.150 mmol), 5 mL of trifluoroacetic acid and 5 mL of dichloromethane were placed in a 25 mL eggplant-shaped bottle and stirred to dissolve. The reaction was completed after 2 h. The solvent was removed by vortexing, the pH was adjusted to 7-8 with saturated sodium bicarbonate, and water and dichloromethane were added for extraction. The mixture was dried by vortexing to obtain compound (4d), 101 mg of a yellow solid, which was directly used for the next step without secondary purification.

[0089] S3. Compound (4d) (81 mg, 0.131 mmol) was dissolved in dichloromethane, and DIEA (34 mg, 0.212 mmol) and dansyl chloride compound ((5), 49 mg, 0.157 mmol) were added successively. The mixture was reacted at room temperature for 24 h. The reaction solution was extracted with dichloromethane, washed with 1 M citric acid, dried and the solvent was removed by column chromatography. After the solvent was removed by rotation, a yellow solid was obtained. The yellow solid was dissolved in a solution of n-hexane and dichloromethane (7:1), filtered, and finally compound (6d), i.e., a small molecule fluorescent probe TYZJ-2204 targeting CDK4 / 6 protein, was obtained as a yellow solid with a yield of 28.6%. mp: 156-160℃. 1H-NMR (400MHz, DMSO-d6) δ10.13(s,1H),8.95(d,J=10.2Hz,1H),8.08(d,J=3.1Hz,1H),7.88(d,J=9.1Hz,1H ),7.56-7.46(m,1H),6.87-6.76(m,1H),5.91-5.77(m,1H),3.60(s,4H),3.23-3.14(m,2H),3.14-3.09(m,6 H),3.00-2.89(m,3H),2.45-2.39(m,3H),2.36(d,J=7.3Hz,3H),2.31(s,3H),2.27-2.19(m,2H),2.03-1.94 (m,2H),1.94-1.85(m,2H),1.83-1.72(m,2H),1.66-1.55(m,4H),1.36(d,J=10.3Hz,9H),0.94-0.74(m,1H). 13 C-NMR(100MHz,DMSO-d6)δ202.91,171.03,161.20,158.88,158.66,155.20,151.77,14 5.24,143.59,142.57,136.64,136.38,129.76,129.73,129.58,129.50,128.71,128.2 1,125.81,124.01,119.65,115.51,115.29,107.04,53.42,49.38,48.96,45.51,45.06,42.75,41.11,39.41,32.51,31.76,29.38,28.61,28.02,26.16,25.61,25.00,14.09.

[0090] Alternatively, the reaction scheme is as follows:

[0091]

[0092] The difference from the above case where n=1, 2, 3 or 5 is that: compound (1) is compound (1e), i.e. 3-(2-((tert-butoxycarbonyl)amino)ethoxy)propanoic acid; compound (3) is compound (3e); compound (4) is compound (4e); compound (6) is compound (6e); and the steps include:

[0093] S1, according to the reaction steps of compound (3a) in this example, compound (1e) and Palbociclib (compound (2)) were used to synthesize a yellow solid (3e) with a yield of 85.6%, mp: 197-199 ° C. 1H-NMR (400MHz, DMSO-d6) δ10.22(s,1H),8.97(s,1H),8.08(d,J=3.0Hz,1H),7.89(d,J=9.0Hz,1H),7.5 1(dd,J=9.1,3.0Hz,1H),6.81(t,J=5.8Hz,1H),5.91–5.72(m,1H),3.62(d,J=6.2Hz,5H),3.37(d,J=7. 6Hz,7H),3.18(d,J=5.0Hz,2H),3.12(d,J=4.9Hz,1H),3.09–3.04(m,2H),2.63(t,J=6.6Hz,2H),2.43( s,2H),2.31(s,2H),2.28–2.19(m,2H),1.89(s,2H),1.83–1.74(m,2H),1.63–1.54(m,2H),1.37(s,8H).

[0094] S2. Add the product (3e) (120 mg, 0.181 mmol) to 5 mL of trifluoroacetic acid and 5 mL of dichloromethane in a 25 mL eggplant-shaped bottle and stir to dissolve. After 2 h, the reaction is complete and the solvent is removed by rotation. Adjust the pH to 7-8 with saturated sodium bicarbonate. Add water and dichloromethane to extract and spin dry to obtain 4e, 118 mg of a yellow solid. The next step of reaction is carried out directly without secondary purification.

[0095] S3, product 4e (118 mg, 0.209 mmol) was dissolved in dichloromethane, DIEA (54 mg, 0.418 mmol) and raw material 5 (67.6 mg, 0.258 mmol) were added successively, and the mixture was reacted at room temperature for 24 h. The reaction solution was extracted with dichloromethane, washed with 1M citric acid, dried and the solvent was removed by column chromatography. After the solvent was removed, a yellow solid was obtained, which was dissolved in a solution of n-hexane and dichloromethane (7:1) and filtered to obtain the small molecule fluorescent probe TYZJ-2205 targeting CDK4 / 6 protein, with a yield of 78.6%, mp: 167-170°C. 1H-NMR (400MHz, DMSO-d6) δ10.18(s,1H),8.97(s,1H),8.46(d,J=8.5Hz,1H),8.32(d,J=8.6Hz,1H),8.17–8.08(m,2H),7.99(t,J=5.8Hz,1H), 7.91(d,J=9.0Hz,1H),7.61(ddd,J=11.2,8.6,7.4Hz,2H),7.50(dd,J=9.1,3.0Hz,1H),7.25(d,J=7.5Hz,1H),5.90–5.52(m,1H),3.65–3.49( m,4H),3.42(t,J=6.5Hz,2H),3.31(t,J=5.8Hz,2H),3.20–3.09(m,4H),2.98(q,J=5.8Hz,2H),2.82(s,5H),2.51(p,J=1.9Hz,1H),2.43(d,J= 4.4Hz,5H),2.32(s,4H),2.27–2.20(m,2H),2.00(s,1H),1.94–1.88(m,1H),1.82–1.74(m,1H),1.59(q,J=6.0Hz,2H),1.18(t,J=7.1Hz,1H). 13 C-NMR (101MHz, DMSO-d6) δ202.88,169.25,161.22,158.95,158.69,155.23,151.79,145. 27,143.61,142.55,136.84,136.42,129.77,129.58,129.52,128.54,128.21,125.81,124 .03,119.73,115.53,115.42,107.09,69.19,66.83,60.22,55.37,53.43,49.33,48.90,45 .52,42.72,41.13,40.63,39.37,33.00,31.76,28.03,25.60,21.22,14.09.HRMS(ESI)m / z calcd forC 41 H 50 N9O6S([M+H] + )793.3600; found 793.3599.

[0096] Example 2

[0097] The preparation method of CDK4 / 6 small molecule fluorescent probe, the reaction route is shown in the following formula:

[0098]

[0099]

[0100] The reaction steps include:

[0101] S1, 7-(Diethylamino)-2-oxo-2H-chromone-3-carboxylic acid reacts with sulfuryl chloride to generate a carboxylic acid derivative, which is then reacted with the compound represented by formula (III) through nucleophilic substitution to obtain the compound represented by formula (I).

[0102] Alternatively, S2, 4-(3-phenoxypropyl)-1,3-dioxane-2-en-2-one and chlorosulfonic acid are reacted by sulfonation to obtain an intermediate, the intermediate is subjected to an amidation reaction, and then reacted with the compound represented by formula (III) by nucleophilic substitution to obtain the compound represented by formula (I).

[0103] Alternatively, S3, 4-(1,2,2-triphenylvinyl)benzoic acid and the compound represented by formula (III) undergo an amide condensation reaction to generate the compound represented by formula (I).

[0104] Alternatively, S4, 4-chloro-7-nitrobenzo[c][1,2,5]oxadiazole and the compound represented by formula (III) undergo an amide condensation reaction to generate the compound represented by formula (I).

[0105] Specifically, the specific steps of S1 are:

[0106] In a 50 ml round-bottom flask, add 7-(diethylamino)-2-oxo-2H-chromone-3-carboxylic acid (compound 2306-01, 1.913 mmol, 500 mg), then add SOCl2 (1.913 mmol, 0.14 ml) protected by nitrogen, add 2 drops of DMF, stir and react at room temperature for 1 hour, and the reaction mass is directly concentrated under vacuum; add 5 ml of petroleum ether, stir and filter to obtain compound 2306-02. The reactant does not need to be purified and is directly used in the next step; dissolve compound 2306-02 (0.536 mmol, 135 mg) in DMF, and after 5 minutes, add DIEA (0.894 mmol, 115.5 mg). After 15 minutes, HATU (0.536 mmol, 150 mg) was added, and the reaction mixture was reacted at room temperature for 50 minutes; intermediate 2203-04 (0.447 mmol, 238 mg) was added to the reaction solution; the final mixture was reacted at room temperature for 24 hours. The product was washed with citric acid, and water and dichloromethane were used to extract the product several times. The organic layer was collected and concentrated in vacuo. The crude product was purified by silica gel column chromatography (methanol: dichloromethane = 1:30) to obtain a yellow solid TYZJ-2306, which is a CDK4 / 6 molecular fluorescent

[0107] Probe. Yield 27.4%, mp: 215-218℃.1 H-NMR (400MHz, DMSO-d6) δ10.20(s,1H),8.96(s,1H),8.72-8.58(m,2H),8.07(d,J=3.0Hz,1H),7.87(d,J=9.0Hz,1H) ,7.66(d,J=9.0Hz,1H),7.49(dd,J=9.1,3.1Hz,1H),6.78(dd,J=9.1,2.4Hz,1H),6.61(d,J=2.4Hz,1H),5.91-5.74(m, 1H),3.68-3.58(m,4H),3.51-3.44(m,3H),3.20-3.15(m,2H),3.10(d,J=5.8Hz,2H),2.42(s,5H),2.31(s,3H),2.27- 2.18(m,2H),1.88(s,2H),1.82-1.72(m,3H),1.58(d,J=5.6Hz,2H),1.22(s,2H),1.12(t,J=7.0Hz,6H).HRMS(ESI)m / z calcd forC 42 H 50 N9O6([M+H] + )776.3879; found 776.3875.

[0108] The specific steps of S2 are:

[0109] 4-(3-phenoxypropyl)-1,3-dioxane-2-en-2-one (compound 2307-01, 6.47mmol, 1g) was slowly added to chlorosulfonic acid (6ml) in an ice bath. After 1 hour, the solution was heated to 80°C and refluxed for 6 hours. The resulting mixture was slowly poured into ice water, filtered, washed twice with water, and the precipitate was dissolved in dichloromethane, washed with dichloromethane: petroleum ether (7:1) solution, and dried to obtain 940mg gray crystals (compound 2307-02). Yield: 80.34%, mp: 73-76°C. 1 H-NMR (400MHz, CDCl3) δ8.21 (d, J = 7.5Hz, 1H), 7.68 (d, J = 7.5Hz, 1H).

[0110] The obtained intermediate 2307-02 (2.05mmol, 520mg) was dissolved in 10ml acetonitrile in an ice bath, triethylamine (3.32mmol, 135.34mg) was added, dimethylamine hydrochloride (2.05mmol, 135.34mg) was added after half an hour of reaction, and the mixture was transferred to room temperature and reacted for 2 hours. The reaction solution was concentrated in vacuo, and the crude product was purified by silica gel column chromatography (petroleum ether: ethyl acetate = 30:1) to obtain a white solid 2307-03. Yield: 28%, mp: 90-93℃. 1 H-NMR (400MHz, CDCl3) δ7.90 (d, J = 7.4Hz, 1H), 7.49 (d, J = 7.3Hz, 1H), 2.90 (s, 6H).

[0111] Intermediate 2307-03 (0.213mmol, 58mg) was placed in a 50ml glass jar and dissolved in dichloromethane. After 5 minutes, N,N-diisopropylethylamine (0.3192mmol, 72mg) was added. Intermediate 2203-04 (0.1912mmol, 100mg) was added to the reaction solution. The final mixture was reacted at room temperature for 24 hours. It was extracted with dichloromethane and washed with 1M citric acid solution. The organic layer was collected and concentrated in vacuo. The crude product was purified by silica gel column chromatography (methanol: dichloromethane = 1:30) to obtain yellow solid TYZJ-2307, which is a CDK4 / 6 molecular fluorescent probe. Yield: 56.8%, mp: 187-191℃. 1 H-NMR (400MHz, DMSO-d6) δ10.15(s,1H),8.96(s,1H),8.46(t,J=5.6Hz,1H),8.09(d,J=2.9Hz,1H),7.89(d,J= 9.0Hz,1H),7.83(d,J=8.1Hz,1H),7.50(dd,J=9.1,3.0Hz,1H),6.37(d,J=8.2Hz,1H),5.92-5.69(m,1H),3.73- 3.57(m,4H),3.48-3.41(m,2H),3.38(d,J=7.0Hz,0H),3.22-3.09(m,4H),2.69(s,6H),2.59-2.49(m,4H),2.32 (s,3H),2.28-2.20(m,2H),2.03-1.84(m,4H),1.80-1.71(m,2H),1.59(t,J=6.0Hz,2H),1.09(t,J=7.0Hz,1H). 13C-NMR(101MHz,DMSO-d6)δ202.91,170.78,161.21,158.97,158.72,155.22,1 46.99,145.27,144.81,143.62,142.55,141.88,140.95,136.39,129.76,125. 81,115.48,107.09,105.36,99.09,65.39,53.39,49.29,48.94,44.98,43.09, 41.25,37.93,31.77,30.00,28.03,25.60,23.69,15.63,14.10.HRMS(ESI)m / z calcd for C 36 H 44 N 11 O6S([M+H] + )758.3192; found 758.3191.

[0112] The specific steps of S3 are:

[0113] 4-(1,2,2-triphenylvinyl)benzoic acid (reactant 2308-01, 0.267mmol, 100mg) was placed in a 50ml conical flask and dissolved in dichloromethane; after 5min, DIEA (0.448mmol, 58mg) was added; after 15 minutes, HATU (0.336mmol, 127mg) was added; the reaction mixture was reacted at room temperature for 50 minutes; intermediate 2203-04 (0.224mmol, 119.31mg) was added to the reaction solution. The final mixture was reacted at room temperature for 24 hours; extracted with dichloromethane and washed with 1M citric acid solution; the organic layer was collected and concentrated in vacuo. The crude product was purified by silica gel column chromatography (methanol: dichloromethane = 1:30) to obtain yellow solid TYZJ-2308, which is a CDK4 / 6 molecular fluorescent probe. Yield: 72.14%, mp: 178-181℃. 1H-NMR (400MHz, DMSO-d6) δ10.17(s,1H),8.96(s,1H),8.39(t,J=5.6Hz,1H),8.08(d,J=3.0Hz,1H),7.90(d,J=9.0Hz,1H),7.65–7.5 7(m,2H),7.55–7.46(m,1H),7.18-7.10(m,9H),7.04(d,J=1.8Hz,1H),7.02(d,J=1.8Hz,1H),6.99(d,J=1.9Hz,1H),6.98(d,J=2.3Hz ,2H),6.96-6.95(m,1H),5.94-5.72(m,1H),3.60(q,J=6.1Hz,4H),3.34(s,3H),3.26(q,J=6.6Hz,2H),3.16(d,J=5.0Hz,2H),3.11( d,J=5.3Hz,2H),2.43(s,3H),2.41(s,2H),2.31(s,3H),2.28-2.20(m,3H),1.96-1.84(m,2H),1.81-1.71(m,4H),1.64-1.53(m,2H). 13 C-NMR(101MHz,DMSO-d6)δ202.92,170.86,166.20,161.21,158.97,158.73,155.23,146.48,14 5.25,143.66,143.36,143.25,142.55,141.85,140.30,136.42,132.92,131.10,131.05,130.95 ,129.76,128.40,128.36,128.30,127.26,127.22,127.16,125.80,115.45,107.08,65.40,53. 39,49.26,48.95,45.03,41.21,31.78,30.21,28.03,25.61,25.16,15.64,14.11.HRMS(ESI)m / z calcd for C 55 H 55 N8O4([M+H] + )891.4341; found 891.4340.

[0114] The specific steps of S4 are:

[0115] 4-Chloro-7-nitrobenz[c][1,2,5]oxadiazole (reactant 2309-01, 0.226mmol, 45mg) was placed in a 50ml glass jar and dissolved in dichloromethane. After 5 minutes, DIEA (0.376mmol, 49mg) was added. Intermediate 2203-04 (0.188mmol, 100mg) was added to the reaction solution; the final mixture was reacted at room temperature for 24 hours; extracted with dichloromethane and washed with 1M citric acid solution; the organic layer was collected and concentrated in vacuo; the crude product was purified by silica gel column chromatography (methanol: dichloromethane = 1:30) to obtain yellow solid TYZJ-2309, which is a CDK4 / 6 molecular fluorescent probe. Yield: 56.8%, mp: 207-209℃. 1 H-NMR (400MHz, DMSO-d6) δ10.14(s,1H),9.57(s,1H),8.95(s,1H),8.52(d,J=8.9Hz,1H),8.0 8(s,1H),7.89(d,J=9.0Hz,1H),7.50(d,J=9.1Hz,1H),6.46(d,J=9.0Hz,1H),5.89-5.76(m,1H ),3.62(dd,J=12.9,6.5Hz,4H),3.52(s,2H),3.24-3.08(m,4H),2.53(d,J=11.3Hz,4H),2.31( s,3H),2.24(q,J=8.8Hz,2H),2.00-1.91(m,2H),1.89(s,2H),1.78(s,2H),1.67-1.55(m,2H). 13 C-NMR(101MHz,DMSO-d6)δ202.93,170.66,161.21,158.96,158.71,155.21,145.26,144.94,144.62,143.62,142.54,138.44,136.40,129.75 ,125.80,121.10,115.47,107.08,99.62,53.40,49.26,48.93,44.96, 43.49,41.27,31.77,29.83,28.03,25.60,23.65,14.09.HRMS(ESI)m / z calcd for C 34 H 38 N 11 O6([M+H] + )694.2855; found 694.2857.

[0116] Example 3

[0117] The preparation method of CDK4 / 6 small molecule fluorescent probe, the reaction route is shown in the following formula:

[0118]

[0119] The reaction steps include:

[0120] S1 and compound 01 are subjected to substitution reaction to obtain intermediate 04.

[0121] S2 and compound 03 react to form intermediate 05, which then reacts with intermediate 04 to form intermediate 06.

[0122] S3, intermediate 06 and compound 2203-04 undergo amide condensation reaction to generate compounds TYZJ-2310-2311;

[0123] Alternatively, S4, intermediate 06 and compound 08 undergo amide condensation reaction to generate compound TYZJ-2312.

[0124] When n=2, the steps include:

[0125] S1. Dissolve 7-bromoheptanoic acid (compound 01-a) (584 mg, 2.793 mmol) and NaI (935 mg, 6.425 mmol) in anhydrous acetone and stir overnight under N2 protection. Remove the solvent first, then dissolve the product in dichloromethane. Remove the inorganic salts by filtration. Concentrate the reaction solution and vacuum dry to obtain compound 03-a as a yellow-white solid. The reaction mixture is used for the next reaction without further purification. Yield: 84.8%, mp: 39-41°C. 1 H-NMR (400MHz, DMSO-d6) δ12.03(s,1H),3.29(s,2H),2.22(s,2H),1.72(s,2H),1.50(s,2H),1.32(dt,J=13.1,7.3Hz,4H)

[0126] 7-iodoheptanoic acid (02-a) (02) (10.743 mmol, 2.0166 g) was added to a 50 mL round bottom flask, and 2,3,3-trimethylindole (compound 03, 7.16 mmol, 1.1394 g) was added;

[0127] Then, 15 mL of acetonitrile solvent was added under nitrogen protection, and the mixture was refluxed at 80°C for 24 h. The acetonitrile was removed by vortexing, and a large amount of ethyl acetate was added, and the mixture was stirred vigorously for 1 hour to complete the reaction. The white solid was filtered to obtain product 04-a. Yield: 78.5%, mp: 175-177°C

[0128] S2. Add 2,3,3-trimethylindole (Compound 03, 12.46mmol, 2.0g) to a 50mL eggplant-shaped flask, add acetonitrile 25mL to dissolve the raw materials, then add iodomethane (1.3mmol, 2.3g), and reflux at 80℃ for 12h. At the end of the reaction, a large amount of crystals precipitated from the flask, and then washed three times with acetonitrile to obtain purple crystals, Compound 05, yield: 94.5%. Melting point: 257-259℃. Yield 94.5%.mp:257-259℃. 1 H-NMR (400MHz, DMSO-d6) δ7.92-7.90(m,1H),7.85-7.82(m,1H),7.66-7.59(m,2H),3.97(s,3H),2.76(s,3H),1.53(s,6H).

[0129] 1-(6-carboxyhexyl)-2,3,3-trimethyl-3H-indole-1-iodide (Compound 04-a, 6.043mmol, 2.51g) and malondialdehyde diphenylamine hydrochloride (5.49mmol, 1.142g) were added to a 50mL two-necked flask, 5mL of acetic acid and 5mL of acetic anhydride were injected under nitrogen protection, and 5mL of acetic acid and 5mL of acetic anhydride were refluxed at 80°C. After 4h, the solvent was dried by rotary evaporation, 1,2,3,3-tetramethyl-3H-indole-1-iodide (Compound 05, 5.49mmol, 1.653g), 4mL of pyridine, and 4mL of acetic acid were added to the flask, and refluxed for 2h. After the reaction was completed, the solvent was removed, washed with 1M citric acid, extracted with dichloromethane, and the reaction solution was concentrated and dried under vacuum. Column chromatography was performed using neutral alumina (petroleum ether: dichloromethane = 10:1) to obtain a black gold solid, compound 06-a, with a yield of 92.7%. mp: 289-290°C. 1 H-NMR (400MHz, DMSO-d6) δ9.16 (s, 1H), 8.34 (t, J = 13.1Hz, 2H), 7.62 (d, J = 7. 4Hz,2H),7.45–7.36(m,4H),7.30–7.20(m,2H),6.54(t,J=12.3Hz,1H),6.29 (s,1H),6.26(s,1H),5.77(s,1H),3.60(s,5H),3.30(t,J=7.0Hz,3H),3.09( m,6H),2.70(s,2H),2.18(t,J=8.0Hz,2H),1.97-1.85(m,2H),1.68(s,12H).

[0130] S3. In a 50mL round-bottom flask, dissolve the intermediate compound 06-a (0.204mmol, 127mg) in 10mL dry dichloromethane solvent, add DIEA (0.408mmol, 53mg), stir for 10min, add HATU (0.306mmol, 85.7mg) to the reaction solution, stir for half an hour, and add compound 2203-04 (0.245mmol, 130.5mg) to the reaction solution. After reacting at room temperature for 24h, wash the compound twice with citric acid and saturated brine, dry with anhydrous sodium sulfate and filter, and purify the concentrate by column chromatography (dichloromethane: methanol = 5:1) to obtain compound TYZJ-2310, a blue solid powder, which is a CDK4 / 6 molecular fluorescent probe. Yield: 17.8%. mp: 355-357℃. 1 H-NMR (400MHz, CDCl3) δ8.79(s,1H),8.09(d,J=9.1Hz,1H),8.01(d,J=2.9Hz,1H),7.75(td,J=13.0,3.3Hz,2H),7.34–7.24(m,5H),7.1 8–7.10(m,2H),7.07–6.98(m,2H),6.68(t,J=12.5Hz,1H),6.49(d,J=5.9Hz,1H),6.20-6.07(m,2H),5.89-5.74(m,1H),5.23(s,2H),3.9 1(t,J=7.8Hz,2H),3.68(dt,J=20.7,5.1Hz,4H),3.50(s,3H),3.27(q,J=6.1Hz,2H),3.14(t,J=5.0Hz,2H),2.45(d,J=16.5Hz,5H),2.3 1-2.16(m,8H),2.05-1.92(m,2H),1.86-1.78(m,4H),1.76-1.68(m,19H),1.61(d,J=4.0Hz,16H),1.49-1.30(m,5H),1.25-1.09(m,1H). 13C-NMR (101MHz, CDCl3) δ202.79,173.74,173.04,172.95,171.63,161.42,158.03,157.24,155.55,153.18,152.90,145.24,143 .39,142.74,141.90,141.83,141.10,140.79,130.82,128.84,128.70,126.38,126.04,125.35,125.13,122.20,122.10,113.8 0,110.81,110.38,103.88,103.80,54.12,53.47,49.79,49.57,49.35,49.10,46.06,45.26,44.18,41.36,39.11,35.84,31.57 ,31.22,30.75,29.71,28.34,28.10,28.01,27.96,27.11,26.00,25.78,25.16,24.86,22.71,14.14,14.00,8.68.HRMS(ESI)m / z calcd for C 61 H 75 N 10 O4([M+H] + )1011.5969; found 1011.5972.

[0131] When n=1, the steps include:

[0132] S1. Dissolve 6-bromohexanoic acid (compound 01-b, 2.2094 g, 11.327 mmol) and NaI (3.0999 g, 20.681 mmol) in 10 ml of anhydrous acetone and stir for 5 hours under N2 protection. Remove the solvent first, then dissolve the product in dichloromethane. Remove the inorganic salt by filtration, concentrate the reaction solution and vacuum dry to obtain a yellow-white solid compound 03-b. Yield: 96%, mp: 40-41°C.

[0133] 6-iodohexanoic acid (compound 02-b, 10.32mmol, 2.5g) was added to a 50mL round-bottom flask, iodopropionic acid (compound 03) (6.885mmol, 1.096g) was added, 15mL of acetonitrile solvent was added under nitrogen protection, and refluxed at 80°C for 24h. The acetonitrile was removed by rotation, a large amount of ethyl acetate was added, and the reaction was vigorously stirred for 1 hour to complete the reaction. A white solid was obtained, and the solid was filtered to obtain the intermediate compound 04-b. Yield: 72.8%, mp: 167-171°C.

[0134] S2. Add 2,3,3-trimethylindole (compound 03, 12.46mmol, 2.0g) to a 50mL eggplant-shaped flask, add acetonitrile 25mL to dissolve the raw materials, then add iodomethane (1.3mmol, 2.3g), and reflux at 80℃ for 12h. At the end of the reaction, a large amount of crystals precipitated from the flask, and then washed three times with acetonitrile to obtain purple compound 05. Yield: 94.5%. Melting point: 257-259℃. Yield: 94.5%.mp: 257-259℃. 1 H-NMR (400MHz, DMSO-d6) δ7.92-7.90(m,1H),7.85-7.82(m,1H),7.66-7.59(m,2H),3.97(s,3H),2.76(s,3H),1.53(s,6H).

[0135] 1-(5-carboxypentyl)-2,3,3-trimethyl-3H-indole-1-iodide (compound 04-b, 4.485mmol, 1.8g) and malondialdehyde diphenylamine hydrochloride (4.077mmol, 1.052g) were added to a 50mL two-necked flask, and 5mL of acetic acid and 5mL of acetic anhydride were injected under nitrogen protection, and 5mL of acetic acid and 5mL of acetic anhydride were refluxed at 80°C. After 4h, the solvent was removed by vortexing, and 1,2,3,3-tetramethyl-3H-indole-1-iodide (compound 05, 4.077mmol, 1.227g), 5mL of pyridine and 5mL of acetic acid were added to the flask, and refluxed for 2h. The solvent was removed, washed with 1M citric acid, extracted with dichloromethane, the reaction solution was concentrated and dried under vacuum, and column chromatography was performed using neutral alumina (petroleum ether: dichloromethane = 10:1) to obtain a black gold solid, compound 06-b. Yield: 87.6%. mp: 278-281°C. 1 H-NMR (400MHz, DMSO-d6) δ8.34(t,J=13.1Hz,2H),7.63(d,J=7.4Hz,2H),7.41–7.34(m,4H),7.41–7.18(m,2H),6.58(t,J=12.4Hz,1H),6.30( dd,J=22.4,13.8Hz,2H),4.10(t,J=7.3Hz,2H),3.45-3.28(m,3H),2.20(t,J=7.3Hz,2H),1.69(s,14H),1.55-1.43(m,2H),1.40-1.30(m,2H).

[0136] S3. In a 50mL round-bottom flask, dissolve the intermediate compound 06-b (0.172mmol, 105mg) in 10mL dry dichloromethane solvent, add DIEA (0.258mmol, 33mg), stir for 10 minutes, add HATU (0.258mmol, 73mg) to the reaction solution, stir for half an hour, and add compound 2203-04 (0.2065mmol, 110mg) to the reaction solution. After reacting at room temperature for 12h, wash the compound twice with citric acid and saturated brine, dry with anhydrous sodium sulfate and filter, and purify the concentrate by column chromatography (dichloromethane: methanol = 5:1) to obtain the product TYZJ-2311, a blue solid powder, which is a CDK4 / 6 molecular fluorescent probe. Yield: 42.8%. mp: 346-349℃. 1 H-NMR (400MHz, CDCl3) δ8.79(s,1H),8.09(d,J=9.1Hz,1H),8.01(s,1H),7.76(t,J=13.1Hz,2H),7.35–7.24(m,4H),7.20(s,1H),7.18– 7.11(m,2H),7.01(t,J=8.7Hz,2H),6.67(t,J=12.5Hz,1H),6.47(t,J=5.8Hz,1H),6.20-6.08(m,2H),5.84-5.75(m,1H),3.91(t,J=7.6 Hz,2H),3.74-3.58(m,4H),3.50(s,2H),3.30-3.19(m,2H),3.14(t,J=5.1Hz,2H),3.05(t,J=5.2Hz,2H),2.41(t,J=7.5Hz,5H),2.32-2 .11(m,7H),2.04-1.93(m,2H),1.87-1.77(m,4H),1.73(d,J=7.9Hz,3H),1.61(d,J=2.4Hz,14H),1.50-1.39(m,2H),1.21-1.16(m,1H). 13C-NMR (101MHz, CDCl3) δ198.02,168.69,168.29,166.81,156.67,153.30,152.51,150.79,148.38,148.12,140.5 1,138.65,137.97,137.15,137.08,136.30,136.02,126.01,124.08,123.94,121.70,120.63,120.39,117.45,117 .36,108.93,106.00,105.59,99.19,99.02,72.61,72.30,71.98,49.36,45.09,44.87,44.61,44.36,40.53,36.61 ,34.36,31.42,26.81,26.45,26.04,23.35,23.25,23.21,22.29,21.71,21.03,20.50,20.11,9.24.HRMS(ESI)m / z calcd for C 60 H 73 N 10 O4([M+H] + )997.5811; found 997.5810.

[0137] Preferably, when n=1, step S3 is not used to react with the intermediate compound 2203-04; instead, step S4 is used to react with palbociclib:

[0138] S4. Dissolve compound 06-b (0.285mmol, 0.127g) in 10mL dry dichloromethane solvent in a 50mL round-bottom flask, add DIEA (0.356mmol, 0.046g), stir for 10 minutes, add HATU (0.308mmol, 0.086g) to the reaction solution, stir for half an hour, and then add compound palbociclib (compound 08, 0.2374mmol, 0.145g) to the reaction solution. After reacting at room temperature for 12h, wash the compound twice with citric acid and saturated brine, dry with anhydrous sodium sulfate and filter, and purify the concentrate by column chromatography (dichloromethane: methanol = 20: 1) to obtain the product TYZJ-2312, a blue solid powder, which is a CDK4 / 6 molecular fluorescent probe. Yield: 32%. mp: 340-345℃. 1H-NMR (400MHz, DMSO-d6) δ10.09(s,1H),8.94(s,1H),8.32(td,J=13.1,5.7Hz,2H),8.06(d,J=3.1Hz,1H),7.85(d,J=9.0Hz,1H),7.60(dd,J=12.0 ,7.3Hz,2H),7.51–7.44(m,1H),7.39(d,J=4.1Hz,2H),7.36-7.33(m,2H) ,7.25-7.17(m,2H),6.55(t,J=12.3Hz,1H),6.35-6.17(m,2H),5.88-5.7 1(m,1H),4.18-4.04(m,2H),3.58(d,J=5.8Hz,7H),3.10(dt,J=10.2,4.8 Hz,4H),2.43(s,2H),2.36(t,J=7.2Hz,2H),2.31(s,2H),2.29-2.19(m,2 H),1.89(s,2H),1.76(dd,J=11.9,6.6Hz,4H),1.67(d,J=10.6Hz,11H),1.59(dd,J=9.9,4.2Hz,4H),1.41(d,J=7.5Hz,2H),1.24(d,J=10.9Hz,1H). 13 C-NMR(101MHz,DMSO-d6)δ203.03,173.67,173.01,171.03,161.17,158.74,158.55,155.18,154.46,14 4.95,143.52,143.12,142.52,142.49,141.54,141.41,129.92,128.90,128.73,125.75,125.11,122.91 ,122.71,115.51,111.53,111.43,107.26,103.72,103.48,53.36,49.32,49.29,48.87,45.09,43.70,4 1.15,32.25,31.78,31.47,28.04,27.63,27.40,27.24,26.17,25.63,24.98,14.13.HRMS(ESI)m / zcalcd for C 56 H 66 N9O3([M+H] + )912.5284; found 912.5288.

[0139] Example 4

[0140] Optical activity assay

[0141] This example provides spectral data of the probe molecule.

[0142] The three series of CDK4 / 6 molecular fluorescent probes obtained in Examples 1 to 3 were respectively dissolved in a PBS buffer solution at pH = 7.4 to obtain a solution with a concentration of 10 μM. The fluorescence excitation spectra, fluorescence emission spectra and maximum ultraviolet absorption wavelength of the three series of probes were obtained using an ELISA reader and an ultraviolet spectrophotometer. The results are shown in Tables 1 and Figure 1 As shown, Figure 1 In the figure, (a) shows the fluorescence excitation spectrum (EX) of the fluorescent probes TYZJ-2201 to 2205, (b) shows the fluorescence emission spectrum (EM) of the fluorescent probes TYZJ-2201 to 2205, (c) shows the fluorescence excitation spectrum (EX) of the fluorescent probe TYZJ-2306, (d) shows the fluorescence emission spectrum (EM) of the fluorescent probe TYZJ-2306, (e) shows the fluorescence excitation spectrum (EX) of the fluorescent probe TYZJ-2307, and (f) shows the fluorescence emission spectrum (EM) of the fluorescent probe TYZJ-2307. , (g) represents the fluorescence excitation spectrum (EX) of the fluorescent probe TYZJ-2308, (h) represents the fluorescence emission spectrum (EM) of the fluorescent probe TYZJ-2308, (i) represents the fluorescence excitation spectrum (EX) of the fluorescent probe TYZJ-2309, (j) represents the fluorescence emission spectrum (EM) of the fluorescent probe TYZJ-2309, (k) represents the fluorescence excitation spectrum (EX) of the fluorescent probe TYZJ-2310~2312, and (l) represents the fluorescence emission spectrum (EM) of the fluorescent probe TYZJ-2310~2310.

[0143] Table 1

[0144] Probe molecules UV absorption wavelength (nm) Fluorescence excitation wavelength (nm) Fluorescence emission wavelength (nm) TYZJ-2201 384.5 371.4 527.8 TYZJ-2202 375.5 370.0 526.2 TYZJ-2203 379.0 371.2 530.0 TYZJ-2204 382.0 369.0 529.0 TYZJ-2205 378.5 368.4 530.0 TYZJ-2306 428.0 415.6 481.8 TYZJ-2307 388.0 371.2 532.0 TYZJ-2308 370.5 637.8 528.0 TYZJ-2309 360.0 483.8 536.6 TYZJ-2310 610.0 / 645.0 641.4 658.0 TYZJ-2311 610.0 / 647.0 642.8 659.0 TYZJ-2312 615.0 / 647.0 642.4 657.8

[0145] Example 5

[0146] Enzyme activity assay

[0147] This example shows the affinity of the probe molecule for the two kinases.

[0148] All enzymatic reactions in this example were carried out at 30° C. for 40 minutes. A reaction mixture was prepared, which contained 40 mM Tris (tromethamine, pH 7.4), 10 mM MgCl2 (magnesium chloride), 0.1 mg / ml BSA (bovine serum albumin), 1 mM DTT (dithiothreitol), 10 μM ATP (adenosine triphosphate), 0.2 ug / ml kinase (one of CDK4 or CDK6) and 100 μM lipid substrate (in this example, the lipid substrate was a commercially available lipid substrate for measuring PI-3 kinase activity). The compound (the compound was selected from one of the various fluorescent probes prepared in Examples 1 to 3) was diluted with 10% dimethyl sulfoxide to obtain a diluent, and then 5 μl of the diluent was added to 50 μl of the reaction mixture, so that the final concentration of dimethyl sulfoxide in all reactions was 1%.

[0149] The assay is performed using the Kinase-Glo Plus Luminescent Kinase Assay Kit, which measures kinase activity by quantifying the amount of ATP remaining in solution after the kinase reaction. The luminescent signal generated by the assay is related to the amount of ATP present and inversely proportional to the amount of kinase activity. 50 Values ​​were calculated by normalized dose-response fit nonlinear regression using Prism GraphPad software.

[0150] Table 2 shows the affinity results of the target compounds in Example 4 for cell cycle-dependent kinase 4 / 6; among them, there are three series: TYZJ-2201~TYZJ-2205 are prepared in Example 1, TYZJ-2306~TYZJ-2309 are prepared in Example 2, and TYZJ-2310~TYZJ-2312 are prepared in Example 3.

[0151] Table 2

[0152] Probe molecules <![CDATA[CDK4 IC 50 (nM)]]> <![CDATA[CDK6 IC 50 (nM)]]> TYZJ-2201 324 548 TYZJ-2202 1595 1812 TYZJ-2203 151 193 TYZJ-2204 2040 3611 TYZJ-2205 2008 3613 TYZJ-2306 284 874 TYZJ-2307 658 1055 TYZJ-2308 1936 5135 TYZJ-2309 90 156 TYZJ-2310 445 1067 TYZJ-2311 170 267 TYZJ-2312 99 184 Palbociclib 11 17

[0153] It can be seen that these three series of probes have affinity for CDK4 / 6 protein. In each series, there is a group of compounds with good enzyme activity. Among the three series of probes, TYZJ-2203 of series 1 is better than the probes of the same series, indicating that the shortening of the carbon chain of the linker group may be beneficial to the binding of the probe molecule to CDK4 / 6. TYZJ-2309 of series 2 has better affinity for CDK4 / 6 than the probes of the same series. We believe that the introduction of a fluorophore with a nitro group may be beneficial to the binding with CDK4 / 6, but the toxicity of the nitro group is not ruled out. TYZJ-2312 of series 3 has a stronger affinity for CDK4 / 6 than the probes of the same series, indicating that reducing the carbon chain of the linker group may be beneficial to the binding of the probe molecule to CDK4 / 6. It has important guiding significance for the further development of CDK4 / 6 probes with better activity.

[0154] Example 6

[0155] Cell viability assay

[0156] This example shows the effect of the probe molecules TYZJ-2201 to TYZJ-2205 obtained in Example 1 on the cell activity of human breast cancer cells MCF-7 and MDA-MB-231.

[0157] Logarithmic phase breast cancer cells MCF-7 and MDA-MB-231 were inoculated into 96-well plates respectively. After the cells adhered to the wall, the probe molecules TYZJ-2201 to TYZJ-2205 obtained in Example 1 were added in a concentration gradient. Three replicate wells were set for each concentration of each probe molecule. In addition, at least six wells were left in each 96-well plate as a blank control group. Since the outermost circle of the 96-well plate evaporated too quickly, in order to avoid the experimental error caused by it, we added 100 μL PBS to the outermost circle of the 96-well plate and then cultured it for another 72 hours. After that, 10 μL of CCK-8 (cell counting reagent) working solution was added to each well and incubated for 30 minutes. The OD value was read with an enzyme reader at a wavelength of 450nm. The data is shown as follows. Figure 2 As shown, (a) shows the results of the cell activity effect on breast cancer cells MDA-MB-231, and (b) shows the results of the cell activity effect on breast cancer cells MCF-7.

[0158] pass Figure 2 It can be seen from the data that the probe molecules TYZJ-2201~TYZJ-2205 have no obvious cytotoxicity to MCF-7 and MDA-MB-231, which is conducive to the subsequent biological evaluation experiments.

[0159] Example 7

[0160] Cell cycle assay

[0161] This example shows the effect of the probe molecules TYZJ-2201 to TYZJ-2205 obtained in Example 1 on the cell cycle of breast cancer cells MCF-7 and MDA-MB-231.

[0162] Logarithmic breast cancer cells MCF-7 and MDA-MB-231 were inoculated in 6-well plates. After the cells adhered to the wall, the probe obtained in Example 1 was added to the wells so that the concentration of the compound in each well was 5 μM. After incubation for 24 hours, all cells were collected, washed with PBS and centrifuged, and fixed with 75% ethanol for more than 2 hours. After fixation, PBS was washed, centrifuged, and RNAse and PI dye were added to incubate in the dark for 30 minutes before detection on a flow cytometer. The obtained data are shown in Tables 3 and 4; wherein Table 3 shows the cell cycle arrest of MDA-MB-231 cells by probe molecules TYZJ-2201 to TYZJ-2205, and Table 4 shows the cell cycle arrest of MCF-7 cells by probe molecules TYZJ-2201 to TYZJ-2205.

[0163] Table 3

[0164]

[0165]

[0166] Table 4

[0167]

[0168] It can be seen from Table 3 and Table 4 that the experimental group with the addition of probe molecules TYZJ-2201 to TYZJ-2205 can block the G1 / S phase of two breast cancer cells compared with the normal growth tumor cell con group, indicating that the series of probe molecules obtained in Example 1 can inhibit the transition from G1 phase to S phase, and the blocking effect on MDA-MB-231 cells is more obvious. This cycle blocking experiment is to preliminarily verify whether the positive drug Palbociclib still has cycle blocking properties after structural modification and transformation, and to select suitable compounds and cell lines for subsequent experiments.

[0169] Example 8

[0170] Cell Imaging Studies Using Probe Molecules

[0171] This example provides the cell imaging effects of the probe molecules TYZJ-2201 to TYZJ-2205 obtained in Example 1 on breast cancer cells MDA-MB-231.

[0172] Logarithmic breast cancer cells MDA-MB-231 were inoculated in a confocal dish, and after the cells adhered to the wall, one of the probe molecules TYZJ-2201 to TYZJ-2205 was added at a concentration of 10 μM ( Figure 3 denoted as probe in the figure), and acridine orange dye ( Figure 3 After staining for 20 minutes, the images were taken under a confocal microscope. Figure 3shown.

[0173] pass Figure 3 It can be seen that the probe molecules TYZJ-2201 to TYZJ-2205 and acridine orange dye all showed strong fluorescence signals, indicating that they can be used to mark breast cancer cells.

[0174] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. For those skilled in the art, the present invention may have various modifications and variations. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present invention shall be included in the protection scope of the present invention.

Claims

1. A CDK4 / 6 small molecule fluorescent probe, characterized in that: It has the structure shown in formula (I): Wherein, R1 is selected from any one of the following structures: or n=1, 2, 3 or 5.

2. A CDK4 / 6 small molecule fluorescent probe, characterized in that: It has the structure shown in formula (I): Wherein, R1 is selected from any one of the following structures: or m=1 or 2.

3. A method for preparing a CDK4 / 6 small molecule fluorescent probe as claimed in claim 1 or 2, characterized in that: The steps include: Palbociclib is subjected to an amidation reaction with a compound represented by formula (II) to generate a compound represented by formula (III), and the compound represented by formula (III) is subjected to an amide condensation reaction with dansyl chloride after deprotection to obtain a compound represented by formula (I); n=1, 2, 3 or 5, or formula (II); n=1, 2, 3 or 5, formula (III); Alternatively, Palbociclib is subjected to an amidation reaction with 3-(2-((tert-butoxycarbonyl)amino)ethoxy)propionic acid to generate a compound, and the generated compound is subjected to an amide condensation reaction with dansyl chloride after deprotection to obtain a compound represented by formula (I); Alternatively, 7-(diethylamino)-2-oxo-2H-chromone-3-carboxylic acid is reacted with sulfuryl chloride to generate a carboxylic acid derivative, which is then reacted with the compound represented by formula (III) through a nucleophilic substitution reaction to obtain the compound represented by formula (I); Alternatively, 4-(3-phenoxypropyl)-1,3-dioxane-2-en-2-one is reacted with chlorosulfonic acid through a sulfonation reaction to obtain an intermediate, the intermediate is subjected to an amidation reaction, and then reacted with the compound represented by formula (III) through a nucleophilic substitution reaction to obtain the compound represented by formula (I); Alternatively, 4-(1,2,2-triphenylvinyl)benzoic acid and the compound represented by formula (III) are reacted by amide condensation to generate the compound represented by formula (I); Alternatively, 4-chloro-7-nitrobenzo[c][1,2,5]oxadiazole and the compound represented by formula (III) are reacted by amide condensation to generate the compound represented by formula (I); Alternatively, the compound represented by formula (IV) is subjected to a halogenation reaction and then reacted with 2,3,3-trimethylindole. The reaction product is reacted with the compound represented by formula (V), and then reacted with the compound represented by formula (III) or Palbociclib to generate the compound represented by formula (I) through an amide condensation reaction; the compound represented by formula (V) is obtained by alkylation of 2,3,3-trimethylindole; 4. The method for preparing the CDK4 / 6 small molecule fluorescent probe according to claim 3, characterized in that: The compound represented by formula (II) reacts with Palbociclib in the presence of DIEA and HATU to generate the compound represented by formula (III), the compound represented by formula (III) reacts with trifluoroacetic acid to remove the protecting group, and then undergoes an amide condensation reaction with dansyl chloride in the presence of DIEA to generate the compound represented by formula (I).

5. The method for preparing the CDK4 / 6 small molecule fluorescent probe according to claim 3, characterized in that: SOCl2 is added to 7-(diethylamino)-2-oxo-2H-chromone-3-carboxylic acid under nitrogen protection, and DMF is added to react to obtain a carboxylic acid derivative. DIEA and HATU are added to the carboxylic acid derivative in sequence to react, and then the compound represented by formula (III) is added to carry out nucleophilic substitution reaction to generate the compound represented by formula (I).

6. The method for preparing the CDK4 / 6 small molecule fluorescent probe according to claim 3, characterized in that: Chlorosulfonic acid is added to 4-(3-phenoxypropyl)-1,3-dioxane-2-en-2-one under ice bath conditions, followed by heating under reflux to obtain an intermediate, triethylamine is added to the intermediate under ice bath conditions for reaction, dimethylamine hydrochloride is then added for reaction, N,N-diisopropylethylamine is added for reaction, and then the compound represented by formula (III) is added for nucleophilic substitution reaction to generate the compound represented by formula (I).

7. The method for preparing the CDK4 / 6 small molecule fluorescent probe according to claim 3, characterized in that: N,N-diisopropylethylamine and HATU are added to 4-(1,2,2-triphenylvinyl)benzoic acid in sequence for reaction, and then the compound represented by formula (III) undergoes a nucleophilic substitution reaction to generate a compound represented by formula (I).

8. The method for preparing the CDK4 / 6 small molecule fluorescent probe according to claim 3, characterized in that: 4-chloro-7-nitrobenzo[c][1,2,5]oxadiazole is added to N,N-diisopropylethylamine for reaction, and then undergoes a nucleophilic substitution reaction with the compound represented by formula (III) to generate a compound represented by formula (I); Optionally, the compound represented by formula (IV) reacts with NaI under N2 reaction to undergo halogenation reaction; then ethyl acetate is added for reaction, and then 2,3,3-trimethylindole is added for reaction to obtain compound 04; 2,3,3-trimethylindole is refluxed with methyl iodide to precipitate crystals of compound 05; malondialdehyde diphenylamine hydrochloride is added to the reaction product 04 and mixed, and then acetic acid and acetic anhydride are added under nitrogen protection for reflux reaction; then compound 05, pyridine and acetic acid are added for reflux reaction to obtain compound 06; DIEA and HATU are added to compound 06 in sequence, and then the compound represented by formula (III) is added for nucleophilic substitution reaction to generate the compound represented by formula (I); n = 1 or 2; Alternatively, after obtaining compound 06, DIEA and HATU are added to compound 06 in sequence, and then Palbociclib is added to carry out a nucleophilic substitution reaction to generate a compound represented by formula (I).

9. Use of a CDK4 / 6 small molecule fluorescent probe as claimed in any one of claims 1 to 2 and / or a CDK4 / 6 small molecule fluorescent probe prepared by the preparation method of the CDK4 / 6 small molecule fluorescent probe as claimed in any one of claims 3 to 8, characterized in that: The applications include: applications in identifying CDK4 / 6 protein and / or preparing products identifying CDK4 / 6 protein.

10. An application of the CDK4 / 6 small molecule fluorescent probe as claimed in claim 1 and / or the CDK4 / 6 small molecule fluorescent probe prepared by the preparation method of the CDK4 / 6 small molecule fluorescent probe as claimed in any one of claims 3 to 8, characterized in that: The applications include: application in cell cycle arrest and / or preparation of cell cycle arrest products; Alternatively, the invention can be used in cancer cell fluorescence imaging and / or in the preparation of cancer cell fluorescence imaging products.

Citation Information

Patent Citations

  • Anticancer intermediate based on PKI-587 and polyethylene glycol coupled anticancer drug, and preparation methods and application thereof

    CN107670050A

  • 99mTc(CO)3 nucleus-labeled isonitrile-containing palbociclib derivative and preparation method and application thereof

    CN109320557A

  • Compound for inhibiting and degrading CDK

    CN109516989A

  • Conjugates of kinase inhibitors and cyanine dyes

    US20190343958A1

  • Prodrug kit for multi-pronged chemotherapy

    WO2024008833A1

Cited By

  • Targeting CDK4 / 6 molecular imaging probe labeling precursor, probe and preparation method and application of targeting CDK4 / 6 molecular imaging probe labeling precursor

    CN120483984A

  • A molecular imaging probe targeting cdk4 / 6, a labeling precursor, a probe and a preparation method and application thereof

    CN120483984B